A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf
.
Acetylation of ELF5 suppresses breast cancer progression by promoting its degradation and targeting CCND1
2021
npj Precision Oncology
AbstractE74-like ETS transcription factor 5 (ELF5) is involved in a wide spectrum of biological processes, e.g., mammogenesis and tumor progression. We have identified a list of p300-interacting proteins in human breast cancer cells. Among these, ELF5 was found to interact with p300 via acetylation, and the potential acetylation sites were identified as K130, K134, K143, K197, K228, and K245. Furthermore, an ELF5-specific deacetylase, SIRT6, was also identified. Acetylation of ELF5 promoted its
doi:10.1038/s41698-021-00158-3
pmid:33742100
fatcat:kgghgfzfy5g2fikqj7skvzdf5q